Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848055 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
A Phase 1 study of Psoriasis, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT00848055 is a Phase 1 study of Psoriasis that has completed, run by Boehringer Ingelheim. The registered enrollment target is 40 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00848055, a Phase 1 study of Psoriasis, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chronic plaque psoriasis
Conditions Studied
Interventions
- DRUG AbGn168 intravenous infusion
Study Locations (7)
Idaho
- 1240.1.05 Boehringer Ingelheim Investigational Site - Boise
Indiana
- 1240.1.06 Boehringer Ingelheim Investigational Site - Evansville
Maryland
- 1240.1.04 Boehringer Ingelheim Investigational Site - Baltimore
Massachusetts
- 1240.1.02 Boehringer Ingelheim Investigational Site - Boston
New York
- 1240.1.01 Boehringer Ingelheim Investigational Site - New York
Texas
- 1240.1.03 Boehringer Ingelheim Investigational Site - Dallas
Other
- 1240.1.7 Boehringer Ingelheim Investigational Site - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848055
The ClinicalTrials.gov registry entry for NCT00848055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (92% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which AbGn168 intravenous infusion is the first listed.
NCT00848055 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Idaho, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT00848055 about?
NCT00848055 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis". The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chronic plaque psoriasis
What is the current status of trial NCT00848055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-12.
What conditions does trial NCT00848055 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00848055?
The interventions under investigation include: AbGn168 intravenous infusion (DRUG).
Who is sponsoring clinical trial NCT00848055?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848055 being conducted?
This trial has 7 study locations across Idaho, Indiana, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.